[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Herzog CE, Andrassy RJ, Eftekhari F: Childhood cancers: hepatoblastoma. Oncologist; 2000;5(6):445-53
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood cancers: hepatoblastoma.
  • Hepatoblastoma is the most common primary liver tumor in children, accounting for just over 1% of pediatric cancers.
  • The primary treatment is surgical resection, however, chemotherapy plays an important role by increasing the number of tumors that are resectable.
  • The prognosis for patients with resectable tumors is fairly good, however, the outcome for those with nonresectable or recurrent disease is poor.
  • [MeSH-major] Hepatoblastoma / therapy. Liver Neoplasms / therapy

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11110595.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 66
  •  go-up   go-down


2. Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, Ortega JA: Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol; 2008 May 10;26(14):2379-83
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
  • PURPOSE: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB).
  • We therefore decided to revisit the role of doxorubicin for the treatment of HB.
  • METHODS: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval.
  • Of these, 55 experienced progression or recurrence after initial treatment.
  • Eleven (31%) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy.
  • Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome.
  • Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB.
  • Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.


3. Molmenti EP, Wilkinson K, Molmenti H, Roden JS, Squires RH, Fasola CG, Tomlinson G, Nagata DE, D'Amico L, Lopez MJ, Savino LM, Marubashi S, Sanchez EQ, Goldstein RM, Levy MF, Andrews W, Andersen JA, Klintmalm GB: Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. Am J Transplant; 2002 Jul;2(6):535-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population.
  • The purpose of our study was to evaluate the outcome of children who underwent liver transplantation as treatment for unresectable hepatoblastoma.
  • There were nine recipients (five boys, four girls) with a diagnosis of unresectable hepatoblastoma.
  • All recipients received preoperative chemotherapy: 67% received postoperative chemotherapy.
  • The only instance in which AFP levels did not decrease to low or undetectable levels post-transplantation was in the patient with recurrent tumor.
  • Liver transplantation has an established role in the treatment of hepatoblastoma.
  • Early diagnosis and treatment were found to be associated with better results.
  • Response to chemotherapy may be an important factor influencing survival.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Female. Humans. Infant. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12118897.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


Advertisement
4. Ijichi O, Ishikawa S, Shinkoda Y, Tanabe T, Okamoto Y, Takamatsu H, Inomata Y, Kawano Y: Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. Pediatr Transplant; 2006 Aug;10(5):635-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.
  • We describe here a patient with relapsed hepatoblastoma after LDLT who developed heart failure, which was treated with irinotecan hydrochloride (CPT-11).
  • However, LDLT failed to induce complete remission and he was diagnosed as relapsed hepatoblastoma six months after LDLT.
  • After six courses of chemotherapy, he developed congestive heart failure because of anthracycline toxicity.
  • The chemotherapy regimen was therefore switched to irinotecan at 35 mg/m2 daily for three days/wk for two consecutive weeks, and repeated every 28 days.
  • These results suggest that irinotecan may be safely given to a patient with relapsed hepatoblastoma after LDLT without serious side effects and may contribute to prolonging the survival.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy. Liver Transplantation

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857004.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Fuchs J, Rydzynski J, Von Schweinitz D, Bode U, Hecker H, Weinel P, Bürger D, Harms D, Erttmann R, Oldhafer K, Mildenberger H, Study Committee of the Cooperative Pediatric Liver Tumor Study Hb 94 for the German Society for Pediatric Oncology and Hematology: Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer; 2002 Jul 1;95(1):172-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94.
  • BACKGROUND: In the past 20 years, a dramatic improvement in the prognosis of patients with hepatoblastoma (HB) has been achieved by combining surgery with chemotherapy in several national and international trials.
  • A worldwide, unsolved problem remains the treatment of patients with advanced or metastatic HB.
  • The protocol assessed the efficiency of chemotherapy consisting of cisplatin, ifosfamide, and doxorubicin (CDDP/IFO/DOXO) and/or etoposide and carboplatin (VP16/CARBO).
  • Six children (8%) had no surgical treatment.
  • Twenty-two tumors were resected primarily, and 41 children underwent surgery after initial chemotherapy.
  • Forty-eight children received primary chemotherapy with CDDP/IFO/DOXO.
  • Eighteen children with advanced or recurrent HB underwent VP16/CARBO chemotherapy, with a response achieved by 12 children.
  • CONCLUSIONS: The current results underline the necessity of preoperative chemotherapy in all children with HB.
  • [MeSH-major] Hepatoblastoma / therapy. Liver Neoplasms / therapy

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115331.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


6. Niwa A, Umeda K, Awaya T, Yui Y, Matsubara H, Hiramatsu H, Watanabe K, Adachi S, Itoh T, Uemoto S, Nakahata T: Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation. Pediatr Transplant; 2009 Mar;13(2):259-62
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.
  • A four-yr-old boy developed a solitary metastasis nine months after living-related liver transplantation for unresectable hepatoblastoma.
  • High-dose chemotherapy using this conditioning regimen may be feasible for recurrent hepatoblastoma after liver transplantation in terms of safety and anti-tumor activity.
  • [MeSH-major] Hepatoblastoma / secondary. Hepatoblastoma / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Liver Transplantation / methods. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child, Preschool. Graft Rejection. Humans. Male. Prognosis. Recurrence. Tacrolimus / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Transplant. 2009 Mar;13(2):148-9 [18764910.001]
  • (PMID = 18444949.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


7. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J: The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer; 2002 Oct 15;95(8):1795-801
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model.
  • BACKGROUND: The P-glyprotein (P-gp), which is a membrane channel encoded by the MDR1 gene, represents a possible explanation for multidrug resistance in human hepatoblastoma (HB).
  • P-gp shows up-regulation in tumor cells after chemotherapy; however, to date, its exact role in HB has not been described.
  • They also studied the effects of the MDR1 antagonizer PSC 833 on chemotherapy in mice xenotransplanted with HB.
  • METHODS: Resected tumor specimens, including both primary tumors and recurrent tumors, from a child suffering from HB were investigated histologically.
  • MDR1 gene expression levels in the different resected tumors from the patient and in the xenotransplants after treatment were determined with polymerase chain reaction analysis.
  • RESULTS: MDR1 gene expression was increased in the patient's tumors after every course of chemotherapy from 30% to > 190%.
  • In the xenotransplants, MDR1 gene expression was enhanced significantly after chemotherapy (P(CDDP) = 0.008; P(CDDP+PSC) = 0.002).
  • CONCLUSIONS: The current results suggest that MDR1 gene expression and P-gp are a potential mechanism of drug resistance in HB.
  • The chemosensitizer PSC 833 significantly improved the effects of chemotherapy in animals xenotransplanted with HB.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Gene Expression Regulation, Neoplastic. Genes, MDR / genetics. Hepatoblastoma / drug therapy. Hepatoblastoma / genetics. Liver Neoplasms / drug therapy. Liver Neoplasms / genetics. P-Glycoproteins / biosynthesis

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12365029.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclosporins; 0 / P-Glycoproteins; 121584-18-7 / valspodar; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Browne M, Sher D, Grant D, Deluca E, Alonso E, Whitington PF, Superina RA: Survival after liver transplantation for hepatoblastoma: a 2-center experience. J Pediatr Surg; 2008 Nov;43(11):1973-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after liver transplantation for hepatoblastoma: a 2-center experience.
  • PURPOSE: Complete resection with adjuvant chemotherapy is the accepted treatment for hepatoblastoma.
  • The aim of this study is to evaluate our results of liver transplantation (LT) for tumors still unresectable after adequate chemotherapy.
  • METHODS: All patients transplanted for hepatoblastoma from 2 institutions between 1990 and 2004 were included.
  • Variables reviewed to determine impact on survival included the following: previous tumor resection, metastatic disease at diagnosis, microscopic vascular invasion, alpha-fetoprotein (AFP) levels at diagnosis and at transplant, tumor histology, and administration of posttransplantation chemotherapy.
  • Effectiveness of pretransplantation chemotherapy was defined as a drop of more than 99% in peak AFP levels.
  • All deaths were secondary to recurrent tumor.
  • Similarly, patients who received posttransplantation chemotherapy had 100% survival compared with 56% without chemotherapy (P = .08).
  • CONCLUSIONS: Liver transplantation is a successful treatment option for children with unresectable hepatoblastoma with a 90% survival rate for primary transplantation.
  • Rescue LT for recurrent hepatoblastoma after previous resection has a poor survival outcome and should be considered a relative contraindication.
  • Posttransplantation chemotherapy improves survival.
  • Until that time, patients who receive rescue transplants should receive posttransplantation chemotherapy.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation / mortality
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Hospitals, Pediatric / statistics & numerical data. Hospitals, University / statistics & numerical data. Humans. Infant. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Staging. Patient Selection. Retrospective Studies. Risk Factors. Survival Analysis. alpha-Fetoproteins / analysis


9. Qayed M, Powell C, Morgan ER, Haugen M, Katzenstein HM: Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer; 2010 May;54(5):761-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan as maintenance therapy in high-risk hepatoblastoma.
  • Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies.
  • All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free.
  • Treatment was well tolerated with minimal toxicity.
  • Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2010 May;54(5):661-2 [20108333.001]
  • (PMID = 20063426.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Matsunaga T, Sasaki F, Ohira M, Hashizume K, Hayashi A, Hayashi Y, Mugishima H, Ohnuma N, Japanese Study Group for Pediatric Liver Tumor: Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int; 2003 May;19(3):142-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma.
  • For better total survival rate of children with hepatoblastoma, the therapeutic strategy for recurrent or metastatic hepatoblastoma should be improved.
  • From 1991 to 1999, 134 cases of hepatoblastoma were treated by surgery and combination chemotherapy of cisplatin (CDDP) and THP-Adriamycin (THP-ADR) based on the JPLT-1 protocol.
  • The treatment outcome of these 12 recurrent and 20 metastatic tumors was analyzed.
  • In four recurrent liver tumors, surgical resection was performed in all four cases, and all the patients were alive and well.
  • In eight recurrent lung tumors, surgical resection was performed completely in six cases with unilateral lung disease, and five of the six patients were alive and well.
  • Active surgical intervention to lung metastases and a more intensive chemotherapy to facilitate complete resection of primary hepatic tumor could improve survival rate of children with refractory hepatoblastoma.
  • [MeSH-major] Hepatoblastoma / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Hepatectomy. Humans. Infant. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768314.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Inaba H, Handgretinger R, Furman W, Hale G, Leung W: Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer; 2006 Apr;46(4):501-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic graft-versus-hepatoblastoma effect.
  • Although the survival rate for pediatric patients with hepatoblastoma has improved, prognosis is still poor when the disease is unresectable and refractory to chemotherapy.
  • Herein, we describe a patient with recurrent metastatic hepatoblastoma who received a non-myeloablative hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
  • This patient's clinical course provides evidence for the probable existence of allogeneic graft-versus-hepatoblastoma effect.
  • [MeSH-major] Bone Neoplasms / therapy. Graft vs Host Disease / immunology. Graft vs Tumor Effect / immunology. Hematopoietic Stem Cell Transplantation. Hepatoblastoma / immunology. Liver Neoplasms / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Disease Progression. Female. Histocompatibility Testing. Humans. Neoplasm Recurrence, Local. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Failure

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806543.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Reyes JD, Carr B, Dvorchik I, Kocoshis S, Jaffe R, Gerber D, Mazariegos GV, Bueno J, Selby R: Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr; 2000 Jun;136(6):795-804
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence.
  • OBJECTIVE: To describe our experience with total hepatectomy and liver transplantation as treatment for primary hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) in children.
  • Systemic (n = 18) and intraarterial (n = 7) neoadjuvant chemotherapy were administered; follow-up ranged from 1 to 185 months.
  • Intraarterial chemotherapy was effective in all patients treated.
  • Intraarterial chemotherapy was effective in 1 of 3 patients.
  • Six patients died of recurrent HCC, and 3 deaths were unrelated to recurrent tumor.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Hepatectomy. Hepatoblastoma / drug therapy. Hepatoblastoma / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Retrospective Studies. Survival Rate


13. Srinivasan P, McCall J, Pritchard J, Dhawan A, Baker A, Vergani GM, Muiesan P, Rela M, David Heaton N: Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation; 2002 Sep 15;74(5):652-5
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthotopic liver transplantation for unresectable hepatoblastoma.
  • BACKGROUND: The outcome of treatment for advanced hepatoblastoma has recently improved after the introduction of preoperative or pre- and postoperative cisplatin-containing chemotherapy combined with complete surgical excision.
  • METHODS: Orthotopic liver transplantation (OLT) was performed in 13 children, aged 5 months to 11 years (median 27 months), who were assessed with unresectable hepatoblastoma, and whose pretreatment extent-of-disease was based on radiologic findings of group III (n=11) and group IV (n=2).
  • One child with a multifocal tumor showed pulmonary metastases at presentation, but, according to radiologic studies, the deposits resolved with chemotherapy before liver transplantation.
  • All 13 patients received preoperative chemotherapy to reduce the size of the primary tumor(s) and to treat metastatic spread.
  • One child shows evidence of recurrent disease in the form of pulmonary metastases.
  • One child underwent emergency OLT for acute liver failure after (incomplete) extended right hepatectomy and died from respiratory failure, with no evidence of recurrent tumor 3 weeks posttransplant.
  • CONCLUSIONS: Liver transplantation is an effective treatment for unresectable unifocal or multifocal hepatoblastoma confined to the liver.
  • A multidisciplinary approach to the management of hepatoblastoma, with thoughtful collaboration between pediatric oncologists, hepatologists, and liver surgeons, is essential.
  • [MeSH-major] Graft Survival / physiology. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation / physiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Lung Neoplasms / secondary. Lymphocytes, Tumor-Infiltrating / immunology. Lymphocytes, Tumor-Infiltrating / pathology. Neoplasm Staging. Survival Rate. Time Factors. Treatment Outcome


14. Pimpalwar AP, Sharif K, Ramani P, Stevens M, Grundy R, Morland B, Lloyd C, Kelly DA, Buckles JA, de Ville De Goyet J: Strategy for hepatoblastoma management: Transplant versus nontransplant surgery. J Pediatr Surg; 2002 Feb;37(2):240-5
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategy for hepatoblastoma management: Transplant versus nontransplant surgery.
  • BACKGROUND: Liver transplantation now is proposed for managing selected hepatoblastoma cases.
  • METHODS: The case records of 34 children with hepatoblastoma treated over a period of 10 years (1991 to 2000) were reviewed retrospectively.
  • RESULTS: All patients benefited from preoperative chemotherapy.
  • Twelve patients, in absence of residual metastasis, underwent liver transplant because the tumour remained unresectable after chemotherapy.
  • Two other patients did not undergo surgery because of widespread disease or resistance to chemotherapy.
  • Disease-free survival rates were 95% after surgical resection, 100% when primary transplant was performed in patients with good response to chemotherapy, 60% after transplantation in patients with poor response to chemotherapy, 50% in patients with transplant as second option, and 0% in patients not undergoing surgery.
  • CONCLUSIONS: Transplantation is a potentially curative option for unresectable hepatoblastoma when chemosensitive (decrease in alpha-fetoprotein and decrease in tumour size).
  • Patients with recurrent or resistant disease are not good candidates.
  • [MeSH-major] Hepatectomy / methods. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Reoperation. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11819207.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Olaya Vargas A, Castellanos Toledo A, Rivera Luna R, Cardenas Cardos R, Rivera Ramirez A, Gonzalez Perez R, Escamilla Asiain G: Gemcitabine based chemotherapy in recurrent or advanced pediatric solid tumors: A phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):8574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine based chemotherapy in recurrent or advanced pediatric solid tumors: A phase II study.
  • Advances have been made in treating these patients over the last three decades by apropiate therapy.
  • This dramatic improvement in outcome has led to the estimation that in the year 2000, one in every 1,000 young adults between the ages 20 and 29 years would have been a survivor of childhood cancer; and this due to the chemotherapy.
  • Patients had recurrent or refractory solid tumor; TREATMENT: Gemcitabine alone 800 mg/m2 days 1 and 8 or in combination with cisplatin at 80 mg/m2 day 1.
  • RESULTS: The median age was 7.7 years (2-17) The histopathology was 2 pts with Ewing sarcoma, 2 pts germ cell tumors, 1 pt Wilms tumor, 2 pt rhabdomiosarcoma, 1 pt rethnoblastoma, 1 pt ostheosacoma and 1 pt hepatoblastoma.
  • All patients were previous treated with chemotherapy: 5 pts received VAC (vincristine, adryamicin and cyclophospamide); 3 received ICE (Ifosfamide, cyclophospamide and epirubicin); and 3 pts received: VeIP, VAI and ethoposide- carboplatin.
  • There were 24 courses of chemotherapy.
  • Conclusión: Gemcitabine alone or in combination with cisplatin demostrated some efficacy in patients heavly previous treated with good tolerance, it could be an option for rescue treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Katzenstein HM, Rigsby C, Shaw PH, Mitchell TL, Haut PR, Kletzel M: Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol; 2002 Dec;24(9):751-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutic approaches in the treatment of children with hepatoblastoma.
  • Hepatoblastoma is the most common liver tumor diagnosed in children.
  • Children with persistently unresectable disease, metastatic disease at presentation, recurrent disease, or slowly declining alpha-fetoprotein levels are at high risk for recurrence, exhibit an extremely poor prognosis, and are in desperate need of novel therapeutic agents and strategies.
  • Three patients were treated with tandem high-dose chemotherapy (HDT) with autologous stem cell rescue (two with primary metastatic disease and one with recurrent disease).
  • All three of the patients treated with HDT had relapse (two of them subsequently received irinotecan); the remaining patient underwent surgical resection of a solitary recurrent pulmonary metastasis.
  • None of the three patients treated with HDT remained disease-free, although the patient who underwent surgical resection of a solitary recurrent pulmonary metastasis remains disease-free 6 years from diagnosis.
  • Further exploration of the use of irinotecan is warranted in high-risk patients with hepatoblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Humans. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468918.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


17. Casas-Melley AT, Malatack J, Consolini D, Mann K, Raab C, Flynn L, Woolfrey P, Menendez J, Dunn SP: Successful liver transplant for unresectable hepatoblastoma. J Pediatr Surg; 2007 Jan;42(1):184-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful liver transplant for unresectable hepatoblastoma.
  • BACKGROUND: Treatment of children with stage III and IV hepatoblastoma has shown little improvement with 5-year survival rates of 64% and 25%, respectively (J Clin Oncol 2000;18:2665-75).
  • A timely and organized treatment program including preoperative chemotherapy combined with living donor liver transplantation and postoperative chemotherapy has been used seeking improved long-term survival in stage III and IV cases.
  • METHODS: A retrospective review of 8 patients with stage III and IV hepatoblastoma unresectable by conventional resection were treated with complete hepatectomy and transplantation.
  • RESULTS: Since August of 2001, we have treated 6 patients with stage III hepatoblastoma and 2 patients with initial stage IV hepatoblastoma.
  • These patients (age, 23 months-9 years) had all received extensive chemotherapy or prior resections.
  • After chemotherapy, none had gross tumor documented outside of the liver at time of transplantation.
  • All patients had at least 2 cycles of postoperative chemotherapy.
  • There were 2 late deaths from recurrent disease.
  • CONCLUSION: Complete hepatectomy with living donor liver transplantation provides optimal surgical treatment in unresectable stage III and initial stage IV disease confined to the liver at resection.
  • This series indicates that children tolerate complete hepatectomy, transplantation, and postoperative chemotherapy well.
  • Referral to a transplant center during the first 3 cycles of chemotherapy appears to offers the best opportunity for long-term survival.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Hepatectomy. Humans. Infant. Male. Neoplasm Staging. Retrospective Studies


18. Tiao GM, Bobey N, Allen S, Nieves N, Alonso M, Bucuvalas J, Wells R, Ryckman F: The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr; 2005 Feb;146(2):204-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation.
  • OBJECTIVE: To review our experience in the management of children who present with hepatoblastoma.
  • STUDY DESIGN: Thirty patients treated for hepatoblastoma at a single institution were reviewed.
  • The remaining 15 underwent biopsies, which were followed by chemotherapy.
  • One patient expired during chemotherapy.
  • Three patients presented with stage IV disease and underwent biopsies, which were followed by chemotherapy.
  • One developed recurrent disease.
  • There was no operative mortality during surgical therapy.
  • CONCLUSION: Chemotherapy may reduce tumor size, allowing for conventional resection.
  • [MeSH-major] Hepatoblastoma / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Cross-Sectional Studies. Female. Humans. Infant. Infant, Newborn. Liver / drug effects. Liver / pathology. Liver / surgery. Liver Transplantation. Male. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome


19. Cillo U, Ciarleglio FA, Bassanello M, Brolese A, Vitale A, Boccagni P, Zanus G, Zancan L, D'Antiga L, Dall'igna P, Montin U, Gringeri E, Carraro A, Cappuzzo G, Violi P, Baldessin M, Bridda A, D'Amico DF, Perilongo G: Liver transplantation for the management of hepatoblastoma. Transplant Proc; 2003 Dec;35(8):2983-5
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for the management of hepatoblastoma.
  • INTRODUCTION: Hepatoblastoma (HEP) is the most frequent liver malignancy occurring in childhood.
  • Surgical resection currently represents the gold standard for treatment.
  • In patients with initially unresectable tumors, chemotherapy may induce remarkable reductions in size.
  • Seven patients (4 males and 3 females) underwent OLTx for hepatoblastoma.
  • All patients presented with bilobar liver involvement and had received chemotherapy according to the SIOPEL-1.
  • Actuarial patient survival rates after OLTx for hepatoblastoma are 83.3%, 83.3%, and 56% at 1, 3, and 5 years, respectively.
  • Two patients died owing to recurrent disease after 6 and 60 months, respectively, from transplantation.
  • CONCLUSIONS: Liver transplantation may represent a valid therapeutic option for patients with unresectable HEP, but it is contraindicated in cases of recurrence following previous resection surgery.
  • Neo-adjuvant chemotherapy is of paramount importance to obtain good long-term results.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Recurrence. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome


20. Mejia A, Langnas AN, Shaw BW, Torres C, Sudan DL: Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center. Clin Transplant; 2005 Dec;19(6):721-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center.
  • Hepatoblastoma (HB) is the most common malignant liver tumor in children.
  • The application of living donor liver transplantation (LDLT) in the management of unresectable HB may add new therapeutic opportunities.
  • We evaluated the outcomes of patients who underwent liver transplantation for treatment of unresectable HB in the period between August 1985 and June 2003.
  • Pre-transplant chemotherapy was used in 90% of cases.
  • Three patients died of recurrent disease at 4, 14 and 38 months.
  • The two LDLT recipients were able to get pre-transplant chemotherapy with a rapid decision towards transplantation; both are alive and well at 5.5 and 11 yr post-transplant.
  • Our experience supports the role of LDLT and deceased donor liver transplantation in the management of unresectable HB when waiting times can be detrimental to the patient's survival.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infant. Living Donors. Neoplasm Recurrence, Local. Retrospective Studies


21. Krstovski N, Radlović N, Janić D, Dokmanović L, Smoljanić Z, Sretenović A: [Successful treatment of second hepatoblastoma relapse--case report]. Acta Chir Iugosl; 2009;56(2):105-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of second hepatoblastoma relapse--case report].
  • INTRODUCTION: The prognosis of hepatoblastoma has changed since effective adjuvant chemotherapy had been introduced in 1980's.
  • There is a general agreement that complete resection is the cornerstone of treatment for children with hepapatoblastoma and the only way for eventual cure.
  • CASE REPORT: We describe a boy with relapsed hepatoblastoma presenting with elevated -fetoprotein (AFP) and no visible tumor by ultrasound and computed tomography (CT).
  • The relapse was treated with chemotherapy.
  • Second relapse occurred shortly after therapy was completed, but this time we waited for tumor mass to appear.
  • Combined surgery and chemotherapy resulted in remission status with 48 months of follow up.
  • CONCLUSION: Hepatoblastoma relapse without evidence of tumor is not unusual but its treatment remains controversial.
  • [MeSH-major] Hepatoblastoma / therapy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Male. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780340.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


22. Austin MT, Leys CM, Feurer ID, Lovvorn HN 3rd, O'Neill JA Jr, Pinson CW, Pietsch JB: Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg; 2006 Jan;41(1):182-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Orthotopic liver transplantation (OLT) is the only treatment option for unresectable hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in children.
  • The primary cause of death for both groups was metastatic or recurrent disease, accounting for 54% of deaths in the HB group and 86% in the HCC group (P = .338).
  • Patients with hepatoblastoma were younger (mean age, 2.9 +/- 2.5 vs 10.4 +/- 4.8 years for the HCC group; P < .001) and more likely to receive a living donor organ (16% vs 4%, P = .03).
  • Thus, in conjunction with better chemotherapy regimens, earlier evaluation for OLT in patients with unresectable HB and HCC may result in yet further improved long-term survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Liver Transplantation. Tissue and Organ Procurement / statistics & numerical data
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Databases, Factual. Female. Humans. Infant. Male. Multivariate Analysis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410130.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 231-00-0115
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


23. Wall WJ: Liver transplantation for hepatic and biliary malignancy. Semin Liver Dis; 2000;20(4):425-36
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of liver cancer by transplantation has evolved into a process of selecting early stage tumors that have a high likelihood of cure.
  • Adjuvant and neoadjuvant chemotherapy became part of treatment protocols in many centers at the same time that more stringent criteria for transplant candidacy were applied to patients with cancer, making it difficult to attribute improved results to the chemotherapy.
  • Hepatoblastoma in children can respond very favorably to chemotherapy combined with transplantation.
  • Recent work combining chemotherapy and radiation with transplantation has not had dramatic success at improving cure rates.
  • Patients with metastatic neuroendocrine tumors of the liver can receive good palliation by transplantation, but the majority of patients eventually develop recurrent cancer.
  • [MeSH-major] Biliary Tract Neoplasms / therapy. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Liver Neoplasms / therapy. Liver Transplantation. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Chemoembolization, Therapeutic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Palliative Care. Patient Selection. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200413.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


24. Büyükpamukçu M, Varan A, Haberal M, Büyükpamukçu N, Köksal Y, Coşkun T, Yüce A, Kale G, Akyüz C, Kutluk T: The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: clinical and laboratory findings of five cases. Pediatr Transplant; 2006 Jun;10(4):517-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate clinical and laboratory findings of these patients and the efficacy of liver transplantation in children with hepatocellular carcinoma (HCC) and hepatoblastoma (HB) associated with tyrosinemia.
  • Radiological studies including ultrasound, computed tomography and magnetic resonance imaging showed heterogeneous parenchyma and nodules in the liver.
  • The time from diagnosis of tyrosinemia to HCC or HB ranged from 9.25 to 15.25 yr.
  • All patients were given chemotherapy including cisplatin and adriamycin.
  • They had no treatment after transplantation.
  • One patient was treated with chemotherapy and right hepatectomy.
  • Three months after completing chemotherapy, she had recurrent tumor in the left lobe of the liver and she died with progressive disease.
  • [MeSH-minor] Adolescent. Child. Disease-Free Survival. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Recurrence. Time Factors. Treatment Outcome


25. Arora N, McKiernan PJ, Beath SV, deVille de Goyet J, Kelly DA: Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation. Pediatr Transplant; 2002 Jun;6(3):214-8
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Orthotopic liver transplantation (OLT) is effective therapy for end-stage liver disease but immunosuppression with calcineurin inhibitors (CNI) leads to significant nephrotoxicity, resulting in either a reduction of dosage to below the therapeutic level or omission of the drug altogether.
  • The indications were: nephrotoxicity in two children, requiring re-transplantation for hepatic artery thrombosis and recurrent giant cell hepatitis, respectively; and nephrotoxicity secondary to chemotherapy for hepatoblastoma in the third child.
  • One child had two episodes of mild acute rejection at 5 and 9 weeks post-OLT and one developed chronic rejection requiring re-transplantation at 9 weeks post-OLT.
  • It was effective in preventing early acute rejection, but the combination of Bx and low-dose CNI drugs did not prevent late acute or chronic rejection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Calcineurin Inhibitors. Graft Rejection / prevention & control. Immunosuppressive Agents / therapeutic use. Liver Transplantation. Recombinant Fusion Proteins
  • [MeSH-minor] Child. Drug Therapy, Combination. Female. Graft Survival / drug effects. Humans. Infant. Kidney Diseases / chemically induced. Male. Receptors, Interleukin-2 / antagonists & inhibitors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100505.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / basiliximab
  •  go-up   go-down


26. Häcker FM, von Schweinitz D, Gambazzi F: The relevance of surgical therapy for bilateral and/or multiple pulmonary metastases in children. Eur J Pediatr Surg; 2007 Apr;17(2):84-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relevance of surgical therapy for bilateral and/or multiple pulmonary metastases in children.
  • PURPOSE: Pulmonary surgery is frequently used for the treatment of metastases in children with various malignant diseases.
  • The benefit of an aggressive surgical treatment in children with bilateral and/or multiple pulmonary metastases is still discussed controversially.
  • The primary malignancies were osteosarcoma (n = 4), hepatoblastoma (n = 3), malignant peripheral nerve sheath tumor (n = 1), adrenocortical carcinoma (n = 1) and alveolar rhabdomyosarcoma (n = 1).
  • Preoperative induction chemotherapy with tumor regression and a subsequent decrease in the size and number of pulmonary metastases was mandatory for the surgery of metastases.
  • 5 children underwent re-thoracotomy due to recurrent pulmonary metastases (2 patients: unilateral; 3 patients: bilateral; 1 patient: twice bilateral).
  • 2 patients (20%) died of recurrent metastatic disease (osteosarcoma: 1; adrenocortical carcinoma: 1).
  • CONCLUSION: Complete surgical resection of pulmonary metastases after response to induction chemotherapy may increase survival in carefully selected children, even in cases with multiple and recurrent metastatic disease.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503299.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Karnak I, Emin Senocak M, Kutluk T, Tanyel FC, Büyükpamukçu N: Pulmonary metastases in children: an analysis of surgical spectrum. Eur J Pediatr Surg; 2002 Jun;12(3):151-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary surgery is frequently used for the treatment of metastasis or nodules in children with various types of malignancies.
  • The primaries were osteosarcoma (n = 2), synovial sarcoma (n = 1), fibrosarcoma (n = 1), Ewing's sarcoma (n = 2), mesenchymal chondrosarcoma (n = 1), Wilms' tumour (n = 4), clear-cell sarcoma (n = 1), Hodgkin lymphoma (n = 3), hepatoblastoma (n = 1), hepatocellular carcinoma (n = 1) and haemangioendotheliosarcoma (n = 1).
  • Pulmonary metastases were encountered either at the time of initial diagnosis (22 %) or occurred within 6 months to 5 years.
  • The nodules contained tumour cells in most cases (n = 14) (78 %), mature nephrogenic elements (6 %) and no tumour tissue (16 %) in the remaining cases.
  • Re-thoracotomy was performed in 22 % of cases for the recurrent lesion, which in only one case was a true local recurrence.
  • Therefore combined therapies such as chemotherapy and/or radiotherapy should be continued in the postoperative period.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Pneumonectomy. Retrospective Studies. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101495.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Colombani PM, Lau H, Prabhakaran K, Maley W, Wise B, Schwarz K, Klein A: Cumulative experience with pediatric living related liver transplantation. J Pediatr Surg; 2000 Jan;35(1):9-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time of transplant, 14 of 30 patients were listed as United Network of Organ Sharing (UNOS) status 3, 11 were listed as UNOS status 2B, and 5 were listed as UNOS status 1.
  • Indications for transplant included biliary atresia (n = 21), alpha-1-antitrypsin deficiency (n = 2), hepatitis C (n = 2), giant cell hepatitis (n = 2), hepatoblastoma (n = 1), valproic acid toxicity (n = 1), and hemangioendothelioma (n = 1).
  • Initial tacrolimus therapy was begun at 0.15 mg/kg/dose PO/NG every 12 hours.
  • Complications of immunosuppressive therapy included persistent systemic hypertension (n = 6), renal tubular acidosis (n = 3), short-term hyperglycemia (n = 2), neurotoxicity (n = 2), nephrotoxicity (n = 2), food allergies (n = 8), and posttransplant lymphoproliferative disease (n = 4).
  • Two of 4 had disease progression requiring chemotherapy.
  • There was 1 late death of recurrent disease.
  • [MeSH-minor] Child. Child, Preschool. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Infant. Postoperative Complications

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10646765.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


29. Uckun FM, D'Cruz OJ, Liu XP, Narla RK: Phenylarsonic acid compounds with broad-spectrum and potent cytotoxic activity against human cancer cells. Arzneimittelforschung; 2003;53(6):428-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PHI-380 was also tested and found to be very active against primary tumor cells isolated from surgical biopsy specimens of 14 patients with therapy-refractory non-small cell lung cancer, breast cancer, colon cancer, lymphoma, hepatoblastoma, or Wilm's tumor as well.
  • Because of their broad-spectrum and potent anticancer activity and ability to induce apoptosis in primary tumor cells from therapy-refractory cancer patients, PAA compounds such as PHI-370 and PHI-380 may provide the basis for effective salvage regimens for patients with recurrent cancer.
  • [MeSH-minor] Apoptosis / drug effects. Cell Division / drug effects. Female. Flow Cytometry. Humans. In Situ Nick-End Labeling. Male. Microscopy, Confocal. Multiple Myeloma / prevention & control. Neoplasm Transplantation. Ovarian Neoplasms / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Structure-Activity Relationship. Testicular Neoplasms / prevention & control. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. BENZENEARSONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872614.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 57F9KU116M / benzenearsonic acid
  •  go-up   go-down


30. Palmer RD, Williams DM: Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol; 2003 Jul;41(1):78-80
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Drug Administration Schedule. Humans. Lung Neoplasms / secondary. Male. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Multiple Primary. alpha-Fetoproteins

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12764754.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / alpha-Fetoproteins; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement